- Nachrichtendetail
-
31.05.2024 00:01:22 - *DJ Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
(MORE TO FOLLOW) Dow Jones Newswires
May 30, 2024 18:01 ET (22:01 GMT)
May 30, 2024 18:01 ET (22:01 GMT)
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
NOVARTIS NAM. SF 0,49 | 904278 | Hamburg | 0,000 | 27.06.24 15:22:53 | ±0,000 | ±0,00% | 0,000 | 0,000 | 0,000 | 80,190 |
|
NOVARTIS NAM. ADR 1 | 907122 | Frankfurt | 99,000 | 27.06.24 08:00:58 | -1,000 | -1,00% | 98,600 | 101,000 | 99,000 | 100,000 |
